Purchase this article with an account.
S. Biester, F. Ziemssen, K.-U. Bartz- Schmidt, F. Gelisken; Intravitreal Bevacizumab Treatment for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5028.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Bevacizumab (Avastin®) has been introduced as a new treatment of different opthtalmologic disorders based on the anti-VEGF effect. The aim of this retrospective study was to evaluate the therapeutic effect of intravitreal bevacizumab in diabetic macular edema.
We analysed retrospectively 17 eyes of 15 patients (7 male, 8 female mean age 61.8 years) which were treated with 1.25mg Bevacizumab intravitreally for diabetic macular edema (average of 2.5 injections per eye). Baseline examination included visual acuity, Optical coherence tomography (OCT) (n=17) and fluorescein angiogram (n=16). Mean follow up was 7.8 months (6 -11 months). Two eyes have received focal laser coagulation during follow-up.
Baseline visual acuity was 20/95 and final visual acuity 20/91 (p=0,59). OCT at baseline showed a central retinal thickness of 543µm (SD +175µm). At the last visit, central thickness of the retina was 464µm (SD +210µm), which was statistically significant (p < 0,05).
Bevacizumab offers the possibility to treat the leakage in diabetic macular edema. This retrospective study with a mean follow-up of 8 months showed no significant effect of the intravitreal Bevacizumab injections on visual acuity in diabetic macular edema. On the other hand retinal thickness decreased significantly. This suggests that anti-VEGF therapy may have a place in the treatment of diabetic macular edema. Further studies are necessary to identify the subgroups of diabetic patients who may respond better to the intravitreal anti-VEGF therapy.
This PDF is available to Subscribers Only